Momenta gains on Copaxone challenge

Momenta (NASDAQ:MNTA) gained $0.81 to $13.89 on Friday after FDA accepted for review

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE